Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Neurology board review courses have significantly updated their Alzheimer’s disease content to reflect major clinical breakthroughs that fundamentally changed how neurologists diagnose and treat this devastating condition. These updates are essential for physicians preparing for board certification, as the field has moved from relying solely on clinical presentation to incorporating biomarker-based diagnostic criteria and disease-modifying therapies that can slow cognitive decline. The acceleration of change over the past two years means that older study materials no longer capture the full scope of what the board examination covers. The updates specifically focus on three major developments: FDA-cleared blood biomarker testing approved in May 2025, two disease-modifying drugs that slow cognitive decline by approximately 30 percent in early-stage disease, and revised diagnostic criteria published by the Alzheimer’s Association and National Institute on Aging in 2024 that fundamentally altered how Alzheimer’s disease is defined and identified.
Table of Contents
- What Are the Key Updates to Alzheimer’s Content in Modern Board Review Courses?
- Disease-Modifying Therapies and Their Role in Modern Neurological Practice
- Blood Biomarkers Transform Diagnostic Accessibility
- Revised Diagnostic Criteria and the New Classification System
- Amyloid-Related Imaging Abnormalities and Safety Monitoring
- Integration of Blood Biomarkers into Clinical Workflows
- Future Directions and Emerging Therapies
- Conclusion
What Are the Key Updates to Alzheimer’s Content in Modern Board Review Courses?
Board review courses have completely restructured their Alzheimer’s modules to reflect how diagnosis and classification have changed. Previously, Alzheimer’s disease was defined primarily by clinical syndrome—progressive cognitive decline with memory loss being the hallmark feature. Now, the diagnostic framework incorporates biological biomarkers, meaning neurologists can identify Alzheimer’s pathology in patients who may not yet show significant cognitive symptoms. This represents a fundamental shift in how the disease is conceptualized and taught.
The coursework now emphasizes that Alzheimer’s disease has a preclinical phase, where amyloid and tau pathology exist in the brain but cognitive function remains normal. This is where newly approved treatments like lecanemab and donanemab have shown the greatest benefit. For example, a 50-year-old patient with memory complaints who previously would have been labeled as having mild cognitive impairment may now be identified as having preclinical Alzheimer’s disease through biomarker testing, making them eligible for disease-modifying therapy. Board candidates must understand this distinction because it directly impacts clinical decision-making and patient management.
Disease-Modifying Therapies and Their Role in Modern Neurological Practice
Lecanemab was FDA-approved in January 2023, followed by donanemab in July 2024, marking the first time neurologists could offer treatments that actually slow disease progression rather than merely managing symptoms. Both drugs target amyloid-beta accumulation in the brain, but they differ in administration schedules and their specific mechanisms. Lecanemab requires biweekly intravenous infusions indefinitely, while donanemab uses a two-month titration followed by quarterly infusions, making it more convenient for patients and potentially improving adherence. The clinical benefit, while meaningful, is important to understand with realistic expectations. Both drugs demonstrate approximately 30 percent slowing of cognitive decline in early-stage Alzheimer’s disease over 18 months, not a reversal or cure.
This means a patient who might have declined significantly over two years could show less severe decline, but cognitive changes would still be evident. Board review courses emphasize the importance of patient selection, informed consent, and realistic prognostication when counseling patients about these therapies. However, one critical limitation that board courses stress is that these drugs only work in patients with documented amyloid pathology and mild cognitive impairment or mild dementia—not in preclinical stages or moderate-to-severe dementia. Additionally, both carry a risk of amyloid-related imaging abnormalities (ARIA), where brain imaging may show microhemorrhages or microinfarcts. Data from AAIC 2025 demonstrated that real-world safety profiles were comparable to or better than clinical trial findings, but this remains a consideration that requires baseline MRI, careful patient monitoring, and sometimes dose adjustments or discontinuation.
Blood Biomarkers Transform Diagnostic Accessibility
The FDA’s clearance of the first blood biomarker test for Alzheimer’s disease in May 2025 represents perhaps the most practice-changing development for neurology education. Previously, diagnosis relied on clinical assessment, cognitive testing, and neuroimaging (PET or CSF analysis), all of which are time-consuming and expensive. A simple blood test measuring phosphorylated tau and amyloid-beta levels now allows primary care physicians and neurologists to identify Alzheimer’s pathology without advanced imaging.
This shift has massive implications for how neurologists train and practice. Board review courses now include extensive sections on these biomarkers, their interpretation, their limitations, and how they integrate into the diagnostic pathway. A 65-year-old patient presenting with memory loss can now get a blood test from their primary care doctor; if positive, they can be referred to a neurologist for cognitive testing and potentially imaging confirmation before starting disease-modifying therapy. This democratizes access to diagnosis but also increases the volume of patients neurologists will see, making knowledge of these biomarkers essential for board-certified neurologists.
Revised Diagnostic Criteria and the New Classification System
The 2024 updated diagnostic criteria from the Alzheimer’s Association and National Institute on Aging eliminated the previous categories of preclinical Alzheimer’s disease, mild cognitive impairment, and mild dementia as distinct entities. Instead, the framework now focuses on the presence of biomarkers combined with cognitive status, creating a grid-based classification system.
This means neurologists can now diagnose someone with “Alzheimer’s pathological change” (biomarker positive but cognitively normal), “mild cognitive impairment with Alzheimer’s pathology,” or “dementia with Alzheimer’s pathology.” For board candidates, understanding this new nomenclature is crucial because examination questions increasingly ask about these updated definitions and their clinical implications. The practical challenge is that older textbooks and older review materials may still reference the previous terminology, creating confusion for test-takers. Modern board review courses explicitly address this transition, helping physicians understand both the historical context and the current standard of care.
Amyloid-Related Imaging Abnormalities and Safety Monitoring
One of the most important topics in updated board review content is amyloid-related imaging abnormalities (ARIA), the potential side effects of disease-modifying therapies that neurologists must recognize and manage. ARIA-E (amyloid-related imaging abnormalities—edema) presents as brain swelling and can cause confusion or cognitive decline; ARIA-H (amyloid-related imaging abnormalities—hemorrhage) appears as microhemorrhages. While real-world data from AAIC 2025 showed these complications occurred less frequently than some initially feared, they remain a significant concern that requires proactive monitoring.
Board review courses emphasize that patients on disease-modifying therapies require baseline MRI imaging and regular clinical assessments. Some patients develop ARIA asymptomatically (visible only on imaging), while others develop symptomatic ARIA that necessitates treatment interruption or discontinuation. A 70-year-old on lecanemab who develops new confusion and headaches might have ARIA-E visible on MRI, requiring temporary cessation of the drug and corticosteroid treatment. Neurologists must be able to recognize these presentations and manage them appropriately, making ARIA assessment a likely topic on board examinations.
Integration of Blood Biomarkers into Clinical Workflows
The practical implementation of blood biomarker testing into clinical practice represents a major teaching point in modern board review courses. These tests are not appropriate for everyone with cognitive complaints—they are most useful in patients with objective cognitive decline or subjective cognitive concerns without objective impairment.
The cost, insurance coverage, and interpretation of results all vary depending on which biomarker test is used. Board review courses now include guidance on which biomarkers best predict amyloid pathology (phosphorylated tau variants and amyloid-beta ratios show the strongest predictive value), how to counsel patients about positive results (biomarker positivity does not mean the patient has symptomatic disease), and how to integrate biomarker results with other clinical information. For example, a 60-year-old with subjective memory complaints, an abnormal blood biomarker, and normal neuropsychological testing represents a diagnostic gray zone that requires careful clinical judgment and possibly confirmatory PET imaging.
Future Directions and Emerging Therapies
As board review content continues to evolve, courses are beginning to incorporate information about therapies in development and emerging evidence on combination approaches. Research is exploring whether combining amyloid-targeting therapies with tau-targeting drugs might provide greater benefit than monotherapy, and several tau-targeting compounds are in advanced clinical trials. Neurologists completing board certification now are expected to understand not just current standards of care but also the trajectory of the field and what evidence is being generated.
Additionally, board review courses increasingly emphasize the importance of biomarker-guided treatment selection. Rather than treating all mild cognitive impairment as Alzheimer’s disease, the future of neurology involves confirming Alzheimer’s pathology through biomarkers before initiating expensive and potentially risky therapies. This approach will define standard of care for the next generation of neurologists and is certainly incorporated into current board examination preparation.
Conclusion
Neurology board review courses have substantially updated their Alzheimer’s disease content to reflect a field transformed by disease-modifying therapies, blood biomarker testing, and revised diagnostic criteria based on biological evidence rather than clinical presentation alone. These updates are not optional enhancements but essential components of board examination preparation, as the examination reliably tests candidates on lecanemab and donanemab efficacy, biomarker interpretation, ARIA recognition, and the 2024 diagnostic framework. Physicians preparing for board certification must understand both the capabilities and limitations of these new tools, recognizing that while disease-modifying therapy represents genuine progress, it remains modest in scope and applicable only to selected patient populations.
The field of Alzheimer’s disease continues to evolve rapidly, with real-world evidence accumulating on the safety and long-term efficacy of disease-modifying therapies. Neurologists who remain current with board certification will be better positioned to counsel patients accurately, select appropriate candidates for therapy, and manage complications as they arise. For anyone preparing for neurology board examination, focusing particular attention on the Alzheimer’s disease updates is an investment in both board success and the ability to provide evidence-based care to patients with cognitive decline.
You Might Also Like
- Training Simulations Help Healthcare Workers Understand Alzheimer’s Experience
- Exosome Research Opens New Window Into Alzheimer’s Brain Changes
- Brain Games and Cognitive Exercises Studied for Alzheimer’s Prevention
For more, see NIH MedlinePlus — dementia.
